Rapport Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Cormorant Asset Management, LP, through its associated funds, has reported beneficial ownership of 2,657,521 shares, representing 5.56% of the outstanding common stock of Rapport Therapeutics, Inc.
NASDAQ
Capital International Investors has disclosed a beneficial ownership of 6.1% in Rapport Therapeutics, Inc., holding 2,921,958 shares.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 6.19% of Rapport Therapeutics, Inc. common stock as of March 31, 2026.
NASDAQ
Cormorant Asset Management and Bihua Chen report a 6.35% beneficial ownership stake in Rapport Therapeutics, Inc. common stock.
NASDAQ
BlackRock, Inc. has reported a 5.03% beneficial ownership stake in Rapport Therapeutics Inc. common stock as of December 31, 2025.
NASDAQ
Cormorant Asset Management, LP and Bihua Chen reported a 6.7% beneficial ownership stake in Rapport Therapeutics, Inc. as of September 30, 2025.
NASDAQ
Johnson & Johnson and its subsidiary JJDC have reduced their beneficial ownership in Rapport Therapeutics, Inc. to 4.9% of common stock.
NASDAQ
Third Rock Ventures entities have filed a Schedule 13G, revealing beneficial ownership of 22.2% of Rapport Therapeutics, Inc.'s common stock as of December 31, 2024.